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Abstract
Background: Fusobacterium nucleatum, a well studied bacterium in periodontal diseases, appendicitis, gingivitis,
osteomyelitis and pregnancy complications has recently gained attention due to its association with colorectal
cancer (CRC) progression. Treatment with berberine was shown to reverse F. nucleatum-induced CRC progression in
mice by balancing the growth of opportunistic pathogens in tumor microenvironment. Intestinal microbiota
imbalance and the infections caused by F. nucleatum might be regulated by therapeutic intervention. Hence, we
aimed to predict drug target proteins in F. nucleatum, through subtractive genomics approach and host-pathogen
protein-protein interactions (HP-PPIs). We also carried out enrichment analysis of host interacting partners to
hypothesize the possible mechanisms involved in CRC progression due to F. nucleatum.
Results: In subtractive genomics approach, the essential, virulence and resistance related proteins were retrieved
from RefSeq proteome of F. nucleatum by searching against Database of Essential Genes (DEG), Virulence Factor
Database (VFDB) and Antibiotic Resistance Gene-ANNOTation (ARG-ANNOT) tool respectively. A subsequent
hierarchical screening to identify non-human homologous, metabolic pathway-independent/pathway-specific and
druggable proteins resulted in eight pathway-independent and 27 pathway-specific druggable targets. Co-aggregation
of F. nucleatum with host induces proinflammatory gene expression thereby potentiates tumorigenesis. Hence,
proteins from IBDsite, a database for inflammatory bowel disease (IBD) research and those involved in colorectal
adenocarcinoma as interpreted from The Cancer Genome Atlas (TCGA) were retrieved to predict drug targets
based on HP-PPIs with F. nucleatum proteome. Prediction of HP-PPIs exhibited 186 interactions contributed by
103 host and 76 bacterial proteins. Bacterial interacting partners were accounted as putative targets. And
enrichment analysis of host interacting partners showed statistically enriched terms that were in positive
correlation with CRC, atherosclerosis, cardiovascular, osteoporosis, Alzheimer’s and other diseases.
Conclusion: Subtractive genomics analysis provided a set of target proteins suggested to be indispensable for
survival and pathogenicity of F. nucleatum. These target proteins might be considered for designing potent
inhibitors to abrogate F. nucleatum infections. From enrichment analysis, it was hypothesized that F. nucleatum
infection might enhance CRC progression by simultaneously regulating multiple signaling cascades which could
lead to up-regulation of proinflammatory responses, oncogenes, modulation of host immune defense mechanism and
suppression of DNA repair system.
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Background
Fusobacterium nucleatum is a gram-negative, anaerobic
opportunistic pathogen from bacteroidaceae family that
causes infection by adhering and invading into epithelial
cells of mouth and gut, co-aggregating with other patho-
genic bacteria and eukaryotic cells followed by modulat-
ing host immune responses [1]. F. nucleatum is known
for its role in periodontitis, appendicitis, gingivitis and
invasive infections of head, neck, lung, liver, heart and
brain [2–6]. It is reported as an aetiological agent of
osteomyelitis, particularly in head and neck region of the
patients, who were already affected by chronic periodon-
titis or odontogenic abscess [7]. F. nucleatum can even
pass through umbilical cord and causes pregnancy com-
plications such as preterm birth, stillbirth and neonatal
sepsis [4, 8]. Colonization by highly invasive F. nuclea-
tum in intestine may be considered as useful biomarker
for inflammatory bowel disease (IBD) diagnosis [2].
Whole genome and shotgun sequencing to characterize
microbiota composition of colorectal cancer (CRC) tumor
showed enriched DNA sequence of F. nucleatum ATCC
25586, suspecting its association with CRC [9, 10]. Subse-
quent studies on cell line and mouse tumor xenograft
model showed that adhesion of F. nucleatum via FadA to
E-cadherin on host cells increases CRC tumor growth by
altering E-cadherin/β-catenin signaling and activating its
downstream proinflammatory responses [11]. Accelerated
colonic tumorigenesis due to F. nucleatum was also evi-
denced in adenomatous polyposis coli+/− (APC+/−) mice
by the generation of NF-kB-driven proinflammatory gene
signature shared by human CRC [12]. Studies by Tahara
et al., suggested its pathogenic role since Fusobacterium
enrichment is associated with specific molecular subsets
of CRC such as microsatellite instability (MSI), TP53
mutation, positivity of CpG island methylator phenotype
(CIMP), hMLH1 methylation, CHD7/8 mutation [13]. In
mice, F. nucleatum colonization alters intestinal microbial
community by reducing symbiotic flora and increasing op-
portunistic bacteria and it also induces tumor related host
immune cytokines. Both, the intestinal microbial structure
and host immune defence plays essential role in CRC
progression [14–17]. Berberine treatment was shown to
reverse F. nucleatum mediated imbalance in luminal
microbiota and thereby CRC growth in vivo studies [18].
Although no direct evidences available to characterize
F. nucleatum as causative agent of CRC, these find-
ings suggest the contribution of F. nucleatum enrich-
ment to aggressiveness of CRC and its successive selection
for designing therapeutic strategies. Thus, we focused on
an in silico strategy to select target proteins in F. nuclea-
tum which might be suitable for attenuating Fusobacter-
ium pathogenicity with potent inhibitors.
Computational approaches in particular comparative
and subtractive genomics have been extensively used to
identify novel drug targets in infectious pathogens. These
approaches are powerful, speedy and cost-effective in drug
discovery and development processes compared to con-
ventional methods. Taking this as an advantage, we imple-
mented subtractive genomics approach [19] to predict
drug targets in F. nucleatum which has fetched 33 drug-
gable proteins altogether. Patients with long term IBD
have an increased risk of CRC development [20]. Given
the association between F. nucleatum infections and en-
hanced multiple gene expression in IBD and CRC, host-
pathogen protein-protein interactions (HP-PPIs) were
predicted to suggest putative targets and to hypothesize
the plausible mechanisms in CRC progression provoked
by F. nucleatum infection.
Results and discussion
Subtractive genomics approach
The RefSeq proteome of F. nucleatum ATCC 25586
(NC_003454.faa) encompassing 2046 protein sequences
was retrieved from NCBI bacterial genomes database.
The schematic representation of workflow with number
of permitted genes at each screening step is shown in
Fig. 1.
Essentiality analysis
Database of essential genes (DEG) consists of minimal
gene set that is indispensable for cellular and organism
viability [21]. A search for DEG homologous se-
quences in the proteome of F. nucleatum yielded 1041 hits
(Additional file 1: Table S1) with cut-off e-value >1E-05
and bit score >100, representing their essentiality for bac-
terial survival. Manual cross-checking of each query pro-
tein’s biological function with its attained hit showed that
they are similar in function. Obtained hits were found to
be involved in structural organization, nutritional uptake,
pathogenesis, antibiotic resistance and other essential pro-
cesses for the survival of F. nucleatum.
Analysis of Virulence Factors (VFs)
Genome sequence studies had reported putative VFs in
F. nucleatum [22]. However, explored significance of this
bacterium in various diseases necessitates the search for
novel VFs. Thus, we attempted to predict VFs from
whole proteome of F. nucleatum by searching against
virulence factor database (VFDB) [23] as well as from lit-
erature reports of orthologous subspecies [24–27].
About 121 proteins of the whole proteome were found
to have hits against VFDB with bit score >100 of which,
13 proteins alone were recognized as non-redundant to
the essential proteins list obtained from DEG (Additional
file 1: Table S2). Among them, the importance of few VFs
in bacterial infection is discussed here (i) Hemolysin acti-
vation protein – lyses erythrocytes and creates anaerobic
environment at the site of infection, attacks immune
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system of the host [28] (ii) Fibronectin-binding protein-
like protein A – mediate adhesion of pathogen to host
cells especially to fibronectin and elastin and helps in
invasion [29] (iii) Choline kinase and Choline transport
protein – catalyze phosphorylcholine attachment to
carbohydrate, releasing CMP in lipopolysaccharide metab-
olism [22] (iv) Polysaccharide biosynthesis protein – could
protect pathogen by producing resistance to complement-
mediated killing by the host [30] (v) γ-polyglutamic acid
synthetase – anchors to bacterial surface and helps in its
survival in adverse conditions [31].
In addition, 114 VFs in F. nucleatum were identified
from their homology to the respective proteins in
orthologous subspecies such as polymorphum and vin-
centii [24, 32]. Among them, only 32 VFs were found
to be non-redundant to the essential proteins list
(Additional file 1: Table S2). These VFs include outer
membrane proteins (OMPs), TraT complement resist-
ance protein, transporter, secretion pathway proteins,
serine proteases, periplasmic component of efflux sys-
tem and other. OMPs of F. nucleatum not only medi-
ate adherence with other pathogenic bacteria and
host cells, but also suppress host immune system and
induce cell death in lymphocytes thus, protecting tumor
cells from immune cell attack [33]. TraT complement re-
sistance protein and serine proteases also fight against
host immune system and thus, enhances resistance of
bacterium [34, 35].
Resistance protein analysis
Resistance causing and drug efflux proteins could act as
potential therapeutic targets [36]. Here, we obtained 118
antibiotic resistant genes in F. nucleatum with cut-off
e-value of 1E-05 by employing Antibiotic Resistance
Gene-ANNOTation (ARG-ANNOT) tool and from lit-
erature search of ortholog subsp. of F. nucleatum.
The number of proteins was further narrowed down to
11, as 107 were observed either as essential or virulent
(Additional file 1: Table S3). Some of the noteworthy
proteins include acriflavin resistance proteins B, D, E, β-
lactamase, multi-drug resistant protein, metal dependent
hydrolase, macrolide-efflux protein and zinc metallohy-
drolase. Acriflavin resistance proteins B and E efflux mul-
tiple drugs directly to external surface and make the
bacteria resistant. However, these proteins cannot efflux
basic, hydrophilic aminoglycoside due to their hydropho-
bic cavity which is accomplished by homolog protein,
AcrD. F. nucleatum also acquired resistance to β-lactam
group of antibiotics like penicillin-G due to its ability to
produce β-lactamases [37]. Genome annotation of five dif-
ferent strains of Fusobacterium also revealed the presence
of multidrug resistance proteins and β-lactamases, which
Fig. 1 Schematic representation of workflow and the outcome of each step involved in computational subtractive genomics-based target
identification in F. nucleatum and prediction of HP-PPIs between IBD, CRC dataset of host and F. nucleatum
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was consistent with our results obtained from ARG-
ANNOT.
Non-human homologous proteins
The search in F. nucleatum proteome mined 1097 non-
redundant essential, virulence and resistance datasets.
However, it is necessary to evaluate homology of
these proteins in order to find out non-human hom-
ologous proteins and to design pathogen-specific in-
hibitors [38]. BLASTp search against proteome of
Homo sapiens retrieved 601 non-homolog proteins
out of which, only 237 were observed to be involved
in 70 metabolic pathways of F. nucleatum according to
Kyoto Encyclopedia of Genes and Genomes (KEGG) map-
per (Additional file 2: Table S4 and S5). The remaining
364 pathway-independent proteins were directly consid-
ered for druggability analysis to understand their thera-
peutic potential.
Differential pathway analysis
Manual comparison between the enlisted 70 metabolic
pathways of F. nucleatum and all 278 metabolic path-
ways of human (present in KEGG) resulted in only 18
pathways that are specific to F. nucleatum. These path-
ways were found to possess only 96 non-redundant pro-
teins (Additional file 2: Table S6).
Druggability analysis
A protein is considered as ‘druggable target’ only when
binding of small molecule either drug/vaccine modulates
its function with beneficiary effects to the host [39].
Druggability of pathway-independent proteins
The 364 proteins that do not belong to any metabolic
pathway of F. nucleatum were found to play a key role
in pathway-independent processes such as prokaryotic
cytokinesis, drug efflux, DNA replication, repair, tran-
scription, translation and colonization in host. Hence,
we considered them for druggability screening which
resulted in only eight proteins with therapeutic charac-
teristics. They are acetoacetate metabolism regulatory
protein atoC, acriflavin resistance protein B, cell division
protein FtsZ, flavodoxin, pseudouridine synthase, puta-
tive ribosome biogenesis GTPase RsgA, putative tRNA
(cytidine(34)-2’-O)-methyltransferase and RNA polymer-
ase sigma factor SigA. Functional significance of each of
these proteins is mentioned in Table 1.
Druggability of pathway dependent proteins
From 96 pathogen-specific metabolic pathway proteins,
only 27 proteins involved in 15 pathways were observed
to be druggable in nature. Segregation of these 27 pro-
teins into their metabolic pathways revealed that 12 of
them belong to peptidoglycan biosynthesis pathway
among which, six were also shared by vancomycin resist-
ance and beta-lactam resistance pathways (3 in each).
Further, lipopolysaccharide biosynthesis pathway and
microbial metabolism in diverse environments had five
druggable proteins in each (shared by CAMP resistance
pathway, propionate metabolism, D-alanine metabolism).
Rest of the pathways possessed only one druggable tar-
get protein in each (Table 2). Thus, this study suggested
the crucial pathways for survival of F. nucleatum, which
Table 1 Metabolic pathway-independent druggable proteins
S. No. Gene Protein name Uniprot ID Function
1 FN1275 Acriflavin resistance protein B Q8RE51 Resistant to aminoglycosides such as amikacin, gentamycin,
kanamycin, neomycin and tobromycin as well as to amphiphilic
compounds. Thus, inhibiting AcrB function may lead to
pathogen’s susceptibility to these antibiotics.
2 FN1321 Acetoacetate metabolism regulatory protein atoC Q8RE11 Required for catabolism of short-chain fatty acids. Plays role in
flagella synthesis, sodium (but not potassium) sensitivity and
chemotaxis.
3 ftsZ Cell division protein FtsZ Q8RDQ7 Required for proper localization of division plane during
bacterial cytokinesis. Inhibition of its GTP-dependent
polymerization activity prevents cells to divide
4 FN0724 Flavodoxin Q8RFH4 Acts as an electron acceptor of pyruvate-oxidoreductase
complex. Flavodoxin inhibitors were reported to act against
Helicobacter pylori’s infection that causes gastritis or chronic
peptic ulcers
5 FN0756 Pseudouridine synthase Q8RFE9 Catalyze post-transcriptional modifications of cellular RNAs
i.e., site-specific isomerisation of uridine.
6 rsgA Putative ribosome biogenesis GTPase RsgA Q8R685 Involved in 30S ribosome subunit biogenesis.
7 FN0809 Putative tRNA (cytidine(34)-2’-O)-methyltransferase Q8R673 Methylates 2’-O-ribose group of cytidine present at 34th
position of tRNA anticodon loop.
8 sigA RNA polymerase sigma factor SigA Q8RE13 Essential for survival of bacteria as it regulates transcription
of housekeeping promoters.
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can be targeted for drug discovery in pathway centric
approach.
Peptidoglycan biosynthesis pathway
From the current study, MurA to MurG proteins, D-
alanine–D-alanine ligase (Ddl), penicillin-binding pro-
tein (PBP), cell division protein ftsI of peptidoglycan
biosynthesis pathway were predicted as target proteins in
F. nucleatum. MurA catalyzes the first committed step of
this pathway where it converts UDP-N-acetylglucosamine
(aminosugar) to UDP-N-acetylglucosamine enolpyruvate.
Targeting this protein could be lethal to bacterium as
F. nucleatum contains only one copy of MurA [40].
MurB is also an attractive target as it catalyzes the re-
duction of UNAG-enolpyruvate [41]. MurC, D, E and F
ligases sequentially attach L-alanine, D-glutamate, 2,
6-diaminopimelate and D-alanyl-D-alanine to form UDP-
MurNAc-peptide [42]. Bacteria acquire vancomycin resist-
ance if MurF joins D-Ala-D-Lac or D-Ala-D-Ser to UDP-
MurNAc-tripeptide instead of D-Ala-D-Ala [43]. MurG
catalyzes glycosyl transfer from UDP-GlcNAc to MurNAc
present in lipid I to produce lipid II [44]. Penicillin binding
proteins (PBPs) translocate this lipid II from cytoplasm to
exterior surface of the cell and incorporate into peptidogly-
can layer [45]. Thus, PBP is also an important target pro-
tein for inhibitor development [46]. These proteins are not
only essential for bacterial survival, but also involve in the
pathogenesis by interacting with host cytoskeleton [47].
Hence, targeting this pathway could lead to bacterial lysis
by weakening the rigidity and strength of cell wall. More-
over, lack of homologous counterpart proteins in human
make them an excellent drug targets.
Lipopolysaccharide (LPS) biosynthesis pathway
In LPS biosynthesis pathway, lpxA, lpxC, KdsA, KdsB
and gmhA were considered as valid targets for drug de-
velopment. Enzymes lpxA and lpxC (catalyzes commit-
ted step) contribute to the formation of lipid A which is
a conserved core oligosaccharide region of LPS mole-
cules. Lipid A is responsible for toxic effects of gram-
negative bacterial infection. The target protein KdsB
(CMP-Kdo synthetase) is unique in its direct coupling of
KDO (sugar) to cytosine monophosphate (CMP) in
KDO biosynthesis which is a part of LPS inner core. An-
other druggable protein obtained in this pathway is
gmhA (lpcA) that catalyzes the first step in biosynthesis
of ADP-L-glycero-D-manno heptose [48]. Inhibiting
gmhA would create heptose less core LPS leading to en-
hanced sensitivity of F. nucleatum to even low concen-
tration of novobiocin, detergents and bile salts [49].
Subcellular localization
Prediction of subcellular localization of druggable targets
using various online servers delineated that 29 out of 35
target proteins were located in cytoplasm while the rest
were in membrane (Additional file 2: Table S7). Cyto-
plasmic proteins can be considered for small molecule
drug development while membrane or secreted proteins
for vaccine development.
Host-pathogen protein-protein interactions
As F. nucleatum infects the host through its adherence
and invasiveness, insights into HP-PPIs could help us to
understand the mechanism of infection, disease estab-
lishment and to identify putative drug targets. The
Table 2 Druggable proteins and their metabolic pathways along with accession number
S. No. Uniprot ID No. of Proteins KEGG pathway KEGG ID
1 Q8RIQ1, Q8RDQ3, Q8RDQ2, Q8RDQ1, Q8R635, Q8R5N5,
Q8RDP8, Q8RDQ4, Q8RG00, Q8RFV2, Q8REF2, Q8REA2
12 Peptidoglycan biosynthesis fnu00550
2 Q8RFU2, Q8R691, Q8R6A2, Q8RE91, Q8RFA8 5 Lipopolysaccharide biosynthesis fnu00540
3 Q8RFB7, Q8RED6, Q8R612, Q8R609, Q8RHW6 5 Microbial metabolism in diverse environments fnu01120
4 Q8RGA2, Q8RDQ4, Q8R5N5, Q8RDP8 4 Vancomycin resistance fnu01502
5 Q8RG00, Q8REF2, Q8REA2 3 beta-Lactam resistance fnu01501
6 Q8R612, Q8RHW6 2 D-Alanine metabolism fnu00473
7 Q8R612 1 Chloroalkane and chloroalkene degradation fnu00625
8 Q8RED6 1 Propanoate metabolism fnu00640
9 Q8R612 1 Butanoate metabolism fnu00650
10 Q8RHW6 1 Biosynthesis of secondary metabolites fnu01110
11 Q8RFU2 1 Cationic antimicrobial peptide (CAMP) resistance fnu01503
12 Q8RGT8 1 Two-component system fnu02020
13 Q8REE2 1 Bacterial chemotaxis fnu02030
14 Q8RI43 1 Phosphotransferase system (PTS) fnu02060
15 Q8RHE2 1 Bacterial secretion system fnu03070
Kumar et al. BMC Microbiology  (2016) 16:84 Page 5 of 12
experimentally verified HP-PPIs information is currently
limited for F. nucleatum. In our attempt to predict the
homology based HP-PPIs between F. nucleatum prote-
ome and IBD, CRC related protein dataset of human
using HPIDB yielded 186 interactions, participated by
103 host and 76 pathogenic proteins (Additional file 3:
Table S8). Predicted interactions were based on homolo-
gous HPIs detected by experimental methods such as
two-hybrid pooling approach, surface plasmon reson-
ance, affinity chromatography, far Western blotting,
anti-tag co-immunoprecipitation and nuclear magnetic
resonance in Bacillus anthracis, Yersinia pestis, Franci-
sella tularensis subsp. tularensis SCHU s4, Saccharomy-
ces cerevisiae S288c, Escherichia coli K-12 and E. coli
O157:H7 organisms collected from IntAct, MINT,
BIOGRID, DIP databases. The biological network of
predicted HP-PPIs is presented in Fig. 2. From these
HP-PPIs, the F. nucleatum interacting partners were re-
ported as putative targets while host interacting partners
were validated by enrichment analysis to predict their
biological processes.
Enrichment analysis of host proteins
If a set of proteins are significantly enriched in certain
biological processes or pathways, they are likely to play
similar role in vivo [50]. Hence, pathway, functional, dis-
ease enrichment analysis and functional annotation clus-
tering were carried out to assess predicted HP-PPIs
using Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [51]. This analysis resulted in
significantly enriched 45 pathways, 306 gene ontology
(GO) terms and 21 diseases with minimum count of
three gene set and p-value lower than 0.05 in addition to
47 annotation clusters with cut-off enrichment score
of > 1 and minimum of three terms.
Pathway enrichment analysis
This analysis was performed based on the assessment
that host proteins involved in HPIs possess functional
correlation to the pathways that are relevant to patho-
gen’s infection. Among the obtained pathways from
DAVID Functional Annotation Chart analysis, Wnt
signaling pathway, ECM-receptor interactions, focal
adhesion, toll-like receptor (TLR) signaling and CRC
probably suggest the role of F. nucleatum in adhesion,
invasion into epithelial cells and triggering of signal
transduction pathways that promote CRC [1, 11, 26, 52].
Other attained pathways such as T-cell, B-cell receptor
signaling, T-cell, B-cell activation, antigen processing
and presentation, Lck and Fyn tyrosine kinases in initi-
ation of TCR activation, viral myocarditis indicate the
relevance of F. nucleatum infection to host immune
responses [11, 53–55]. F. nucleatum infection inhibits
T-cell activation by preventing cells to exit G0/G1
phase of cell cycle which may result in local and/or
systemic immunosuppression [53]. Chronic inflamma-
tion in periodontal diseases due to F. nucleatum has
been reported as potential risk factor for Alzheimer’s
disease [56]. Most of the obtained pathways were in
accordance to literature reports while the rest of
them could be either false positive or may have an in-
direct effect which seeks further experimental support.
This include renal cell, basal cell, small cell lung, non-
small cell lung, endometrial, thyroid, pancreatic, acute
myeloid leukemia, glioma, leukocyte transendothelial mi-
gration and melanoma.
Functional and disease enrichment
Similar to pathway enrichment analysis, GO term
analysis of host interacting partners also showed the
involvement of F. nucleatum in Wnt signaling path-
way through β-catenin, T & B cell activation, immune
system development, cell differentiation, cytoskeleton
and apoptosis. GO term analysis also added other
processes including cell proliferation, cell motion,
membrane invagination, cell cycle control, organ de-
velopment, tissue cell and organ morphogenesis, re-
ceptor & lipid binding, blood vessel development,
homeostasis process, embryogenesis, neurogenesis and
others which were also supported by literature (Additional
file 3: Table S10) [26, 27, 53, 55, 57–60].
Disease enrichment analysis of host interacting part-
ners showed the association of F. nucleatum with CRC,
atherosclerosis, cardiovascular diseases, blood pressure,
arterial hypertension, Alzheimer’s and osteoporosis
(Additional file 3: Table S11) [56, 61–63]. Systemic in-
flammation and immune cross-reactivity due to F. nucle-
atum infection play a major role in atherogenesis [62]
and may increase the risk to develop atherosclerotic car-
diovascular diseases, blood pressure [64]. F. nuclea-
tum may play a role in osteoporosis as it is a strong
inducer of osteoclast activity and stimulates bone re-
sorption [65]. Other diseases such as endometrial,
ovarian cancer, melanoma could be either false posi-
tive or may share common signaling pathways with
other diseases of F. nucleatum.
In order to further validate the results, we performed
Functional Annotation Clustering analysis which yielded
47 functional clusters (Additional file 3: Table S12).
Most over-represented terms in this functional cluster
analysis were related to focal adhesion, immune re-
sponses, cell cycle, cell differentiation & death, wnt, p53
pathways and positive regulation of transcription.
Based on this enrichment analysis, we hypothesized
the possible mechanisms involved in CRC progression
due to F. nucleatum infection (Fig. 3). Host epithelial
cells detect F. nucleatum infection via TLRs [52]. Infec-
tion by this bacterium damages the gut tissue by
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Fig. 2 Biological network of host-pathogen protein-protein interactions are shown using Cytoscape. F. nucleatum and host interacting proteins
are represented in pink and blue color respectively
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inducing NF-kB driven overexpression of inflammatory
genes such as collagenase-3, IL-6, 8, 10, TGF-α, TGF-β
(through p38 MAPK activation) and TNF-α [26].
Responding to this damage, epithelial cells stimulate re-
pair and defensive (wound healing) mechanism by pro-
ducing antimicrobial peptide, β-defensins [55]. However,
the bacterium escapes from antimicrobial effects of host
and persists inside epithelial cells possibly by interfering
with phagosome-endosome system [26]. Thus, the cycle
of tissue damage and repair mechanism continues which
might promote tumor induction. Besides, overexpression
of proinflammatory genes could also facilitate tumor in-
vasion and extravasation by regulating the production
and activity of extra cellular matrix degrading proteases.
Proinflammatory genes may enhance the expression of
anti-apoptotic (Bcl2, Bcl-xL), proliferative genes (c-Myc,
cyclin D1) and pro-angiogenesis factor (VEGF) via
STAT3 up-regulation. Localized inflammatory micro-
environment created by up-regulated inflammatory
genes and oxidative damage by ROS possibly induces
DNA mutations and epigenetic changes in host cells.
However, host DNA repair mechanism unable to restore
this damage as F. nucleatum induces the production of
kinases involved in DNA damage (DNA-PK), death-
associated protein kinase 1, protein kinase CK-2 and
COX-2. This results in accumulation of oncogenic or in-
activating mutations in tumor suppressor genes such as
p53 and APC. During F. nucleatum adhesion, downregu-
lated expression of E-cadherin by FadA binding could
lead to epithelial-mesenchymal transition (EMT) due to
enhanced expression of β-catenin-regulated transcrip-
tion factors such as lymphoid enhancer factor (LEF)/
T-cell factor (TCF), NF-kB, Myc and Cyclin D. Thus,
chronic infection of F. nucleatum may alter local cyto-
kine profile, DNA repair system, apoptotic, proliferative
and immune responses in infected cells and modulates
the microenvironment of gut towards CRC.
Conclusion
A set of proteins that were proposed through this com-
putational approach might act as suitable targets for
therapeutic intervention of F. nucleatum. In future, po-
tent inhibitors can be designed to these predicted targets
followed by an experimental verification. This might
help in treatment of periodontal or other diseases caused
by F. nucleatum and to reverse F. nucleatum-induced in-
testinal microbial imbalance in CRC progression. HP-PPIs
predicted from this study might help in further mechanis-
tic and functional exploration of F. nucleatum infection.
Pathway, functional and disease enrichment analysis cor-
roborated that predicted HP-PPIs were closely correspond
to F. nucleatum infection. And the enrichment analysis of
host interacting partners suggested that this bacterium
might enhance CRC progression by affecting multiple sig-
nal transduction pathways, immune responses and tumor
suppressive genes. Thus this study revealed the possible
target proteins in F. nucleatum, predicted host-pathogen
interacting partners and hypothesized the mechanisms in-
volved in CRC progression due to infection of F. nuclea-
tum which altogether may be applied for preventive or
complementary therapy against F. nucleatum.
Methods
The RefSeq proteome of F. nucleatum was downloaded
from NCBI ftp for subtractive genomics analysis and to
predict HP-PPIs.
Fig. 3 The plausible mechanisms in CRC progression due to F. nucleatum infection may involve increased expression of proinflammatory genes,
ROS, oncogenes, DNA damaging genes and β-catenin signaling which may contribute to accumulation of mutations that promote tumor
induction, proliferation and epithelial-mesenchymal transition
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Subtractive genomics approach
Essential proteins
DEG consists of experimentally identified 22,343 essen-
tial protein-coding genes, 646 non-coding RNAs, pro-
moters, regulatory sequences, and replication origins
from 31 prokaryotes and ten eukaryotes [21, 66]. The
queried genes having homologous hit in DEG are likely
to be essential. Thus, BLASTp search was performed for
the proteome of F. nucleatum against DEG bacterial
proteins with cut-off parameters of 1E-05 e-value and
bit score of 100. Query proteins and their corresponding
hits were then manually compared for similar biological
function. Proteins that satisfy these criteria alone were
considered essential for bacterial survival.
Virulence factors
VFs are inherent properties of pathogen which help the
bacteria to adhere, colonize, invade, conquer host defence
mechanism and cause disease. Understanding potential
VFs from F. nucleatum and inhibiting them would make
the pathogen non-virulent. VFDB, a comprehensive data-
base that consists of four categories of VFs namely offen-
sive, defensive, non-specific and virulence-associated
regulated genes from 25 pathogenic bacteria [23]. The
proteome of F. nucleatum was subjected to BLASTp
search against database of protein sequences from VFDB
core dataset (R1) with default parameters. The query se-
quences having hit with cut-off bit score >100 were only
considered as VFs. Additionally, the literature reported
VFs were collected from closely related subspecies of
F. nucleatum including polymorphum and vincentii.
Homology search of these proteins was performed to
find exact matches in F. nucleatum subsp. nucleatum
and thus constituted the list of VFs.
Resistance proteins
Antibiotic therapy is generally used to treat F. nucleatum
infections [67]. However, the bacterium has acquired
resistance to several antibiotics by not only synthesizing
β-lactamase but also by increased production of efflux
proteins [68]. It has also showed resistance to human
β-defensins (antimicrobial peptides) [25] and IgA due
to which there is significant gain in its adherence to
mucosal surfaces and colonization [69, 70]. Thus it is
obligatory to study resistant proteins in F. nucleatum
to prevent its infections. We implemented ARG-
ANNOT tool [71] and literature search in ortholog
subsps of F. nucleatum to identify existing and putative
new antibiotic resistant genes in F. nucleatum. ARG-
ANNOT contains 1689 antibiotic resistant amino acid se-
quences from various classes including aminoglycosides,
beta-lactamases, fosfomycin, fluoroquinolones, glyco-
peptides, macrolide-lincosamidestreptogramin, phenicols,
rifampicin, sulfonamides, tetracyclines and trimethoprim.
A local BLAST program was run for the proteome of
F. nucleatum in Bio-Edit software against antibiotic
resistant sequences in ARG-ANNOT with cut-off e-value
of 1E-05.
Non-homologous proteins to host
BLASTp search of comprised list from the above three
independent searches was performed against non-
redundant protein sequence (nr) database of the host
Homo sapiens (taxid: 9606), with an expected threshold
value of 0.005. Proteins that did not show significant
homology were only considered as non-homologous to
human. These were sorted into their respective meta-
bolic pathways to select pathogen specific pathways. Pro-
teins that do not belong to any of metabolic pathways
were directly considered for druggability screening.
Pathogen specific pathways
KEGG pathway database [72] was used to find out
the metabolic pathways of non-homologous proteins
of F. nucleatum. Similarly, host metabolic pathways
were also enlisted along with their accession number.
The enlisted host and pathogen metabolic pathways were
manually compared to identify the pathways that present
only in the pathogen but not in the host H. sapiens.
Druggable proteins
Druggability of screened proteins was investigated
against all drug targets present in DrugBank database
[73] and Therapeutic Targets Database (TTD) [74] re-
spectively. Drugbank contains 4323 non-redundant pro-
tein sequences including drug target/enzyme/transporter/
carrier linked to 6712 drug entries consisting of 1448
FDA-approved small molecule drugs, 131 FDA-approved
biotech (protein/peptide) drugs, 85 nutraceuticals and
5080 experimental drugs. While TTD contains 2025 tar-
gets, including 364 successful, 286 clinical trial, 44 discon-
tinued and 1331 research targets. The resultant hits from
these two searches with bit score >100 and e-value <0.005
were considered as potential therapeutic candidates. Bio-
logical location of druggable proteins was classified as
either cytoplasmic or membrane proteins based on the
consensus location predicted using various online servers
including PSORTb [75], Secretome [76], Cell-PLoc [77],
CelloGram [78], PSLpred [79], and SOSUI [80].
Host-pathogen protein-protein interactions
HP-PPIs are rich in information to understand mo-
lecular mechanism of pathogenicity. In the current
work, we investigated HP-PPIs of F. nucleatum with
respect to its infection in IBD and CRC. The RefSeq
proteome of pathogen and host gene set was subjected to
homology-based approach [81] implemented in Host-
Pathogen Interaction DabaBase (HPIDB) which integrates
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experimental Protein-Protein Interactions (PPIs) from sev-
eral public databases such as IntAct, GeneRif, Bind, Patric,
VirHostNet, BioGRID, Reactome and MINT. HPIDB pre-
dicts HP-PPIs by serving homologous experimentally de-
rived HP-PPIs as template [82]. The resultant HP-PPIs
were scrutinized manually for similar biological function
with their corresponding homologous and experimentally
validated HP-PPI template given in the output.
Pathway and functional enrichment analysis
The pathway, functional enrichment analysis and gene-
annotation are promising approaches to identify the
most significant and relevant biological processes of
large gene list. Host genes that were predicted to inter-
act with F. nucleatum were validated by Functional An-
notation Clustering tool in DAVID v6.7 [50, 83]. DAVID
provides statistically enriched pathways, diseases and
GO terms for input genes using biological informa-
tion present in pathway (BBID, BIOCARTA, KEGG,
PANTHER and REACTOME), disease (OMIM and
Genetic Association Disease) databases and Gene Ontology
Consortium. The enrichment analytic algorithm used
in this tool performs batch annotation and provides
various annotation categories including GO terms,
disease and pathway associations, protein-protein in-
teractions and others. We have annotated an individual
chart report of host gene list for GO terms, disease associ-
ations and bio-pathways to highlight statistically signifi-
cant enriched terms with count threshold of 3 and EASE
threshold of 0.1. Functional Annotation Clustering of host
gene list with default databases was done to cluster a
group of terms with similar biological function. It implies
kappa statistics and fuzzy heuristics to cluster the data
into an organized biological term modules and calculates
the enrichment scores, p-value (Fisher’s Exact) with
Benjamini correction. The terms with minimum gene
set of 3 and cut-off p-value of 0.05 and clusters with
enrichment score >1.0 were considered significant.
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